Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …

Immune checkpoint inhibitors, including those targeting the programmed cell death
1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are …

Immune checkpoint inhibitors (ICI) have emerged as a remarkable treatment option for
diverse cancer types. Currently, ICIs are approved for an expanding array of cancer …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Highlights•Anticancer drug resistance (ADR) is a primary clinical bottleneck for treatment of
cancers.•Immune checkpoint inhibitors (ICIs) have been revolutionized the treatment for …

Tumor cells predominantly express self-antigens and overcoming self-tolerance is the
primary challenge to effective immunotherapy. Tumors also express ligands for co-inhibitory …

Immune checkpoint inhibitor therapy has revolutionized the field of cancer immunotherapy.
Even though it has shown a durable response in some solid tumors, several patients do not …

Immune check point inhibitors (ICIs) have marked their existence in the field of cancer
immunotherapy. Their existence dates to 2011 when the first anti-cytotoxic T lymphocyte …

Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …